source
- Genentech signs up to develop Alector’s preclinical blood-brain barrier therapy in $1.27 billion dealGenentech, a Roche subsidiary, announced a deal with Alector to obtain exclusive rights to its preclinical blood-brain barrier delivery asset, AL050. The agreement provides $100 million upfront an…
- Nobel Prize honors optogenetics pioneers; Roche licenses Alector’s Parkinson’s enzyme therapyThe Nobel Committee awarded this year’s Physiology or Medicine prize to three scientists whose work created the field of optogenetics. Their discoveries of a light‑sensing protein in algae and its…